2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:

Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
![Davinci Gen V Banner Iamge[39]](/media/whpf0qko/davinci-gen-v-banner-iamge-39.jpg?width=431&height=214&format=webp&quality=100&v=1dbb81c2443a690)
Smiths Interconnect announces significant contract win
Read our company news as Smiths Interconnect announces a significant contract win
Find out more
Smiths Interconnect welcomes new EU-Canada security and defence partnership
Find out more
Smiths Group becomes member of the Manufacturing Technology Centre
Read our latest company news as Smiths Group becomes a member of the Manufacturing Technology Centre
Find out more